Treats iron deficiency anemia (IDA). Sold as Feraheme, Ferabright. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 15, 2026, FDA lists 3 applications for Ferumoxytol (sold as Feraheme, Ferabright), first approved Jun 30, 2009, with 1 new use approved and 0 published complete response letters.
| Feraheme (Q0138) | Part B | $26.5M | -6% | 66,681 |
| Feraheme (Q0139) | Part B | $226K | +21% | 655 |
| Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection FractionHeart Failure With Preserved Ejection Fraction (HFPEF) · University of Florida | Early phase 1 | Recruiting | Jun 9, 2026 |
| Nanozymes in EndodonticsApical Periodontitis, Endodontic Disease · University of Pennsylvania | Phase 4 | Enrolling by invitation | Apr 9, 2026 |
| Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma PatientsGlioblastoma · Jonsson Comprehensive Cancer Center | Phase 3 | Recruiting | Mar 10, 2026 |
| Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous DiseasesVenous Diseases · Min Zhou | Phase 2 | Recruiting | Mar 5, 2026 |
| A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary ArteriesCoronary Artery Calcification · The First Affiliated Hospital with Nanjing Medical University | — | Recruiting | Feb 10, 2026 |
| Handheld MPI Imaging to Track Stem Cells in OsteoarthritisKnee Arthritis Osteoarthritis · Soochow University | Early phase 1 | Enrolling by invitation | Dec 31, 2025 |
| ImmunoMRI for Assessment of Tumor-associated MacrophagesDLBCL - Diffuse Large B Cell Lymphoma · Medical University of Vienna | Early phase 1 | Not yet recruiting | Jul 15, 2025 |
| USPIO Enhanced MR Imaging in CNS Tumours (UMIC)Vestibular Schwannoma, Glioma, Astrocytic · Northern Care Alliance NHS Foundation Trust | Not applicable | Recruiting | Aug 27, 2024 |
| Jun 30, 2009 | FerahemeNDA 22180 · New active ingredient | Azurity | 17 | Marketed |
| Jan 15, 2021 | FerumoxytolANDA 206604 | Sandoz | 1 | Marketed |
| Oct 16, 2025 | FerabrightNDA 219868 · New indication | Azurity | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sandoz